Frontline Forum: Testing and Targeted Therapy in EGFR Exon20+ NSCLC
Experts discuss the current continuum of care for patients with EGFR exon 20 non–small cell lung cancer and findings from studies including the phase 2 CHRYSALIS trial.
Evolving Management of EGFR Exon20+ NSCLC: Future Directions in Care
Closing out their discussion on EGFR Exon20+ non–small cell lung cancer, Joshua Sabari, MD, and Misako Nagasaka, MD, share excitement for future evolutions in the treatment paradigm.
Advanced NSCLC: CNS Penetration With Novel EGFR TKI Therapy
A brief review of novel EGFR TKIs that may have stronger CNS penetration in patients with non–small cell lung cancer and brain metastases.
Factors in Selecting Novel Therapy for Patients With EGFR Exon20+ NSCLC
Following their review of data behind amivantamab and mobocertinib in EGFR Exon20+ non–small cell lung cancer, expert oncologists consider factors that help to inform treatment selection.
EGFR Exon20+ NSCLC: Trial Data With Mobocertinib
Joshua Sabari, MD, and Misako Nagasaka, MD, reflect on clinical trial data and experience with mobocertinib in patients with EGFR Exon20+ non–small cell lung cancer.
Trial Data and Experience With Amivantamab in EGFR Exon20+ NSCLC
Expert perspectives on clinical trial data and personal experience with amivantamab in the setting of EGFR Exon20+ non–small cell lung cancer.
First- and Second-Line Treatment Options for EGFR Exon20+ NSCLC
Key opinion leaders in non–small cell lung cancer management reflect on the current first- and second-line treatment options available to patients with EGFR Exon20+ disease.
Uncommon EGFR Mutations in Advanced Non–Small Cell Lung Cancer
Shared insight on uncommon EGFR mutations in patients with non–small cell lung cancer and how they fit into the larger disease paradigm.
Paradigm of NGS Testing in Patients With Advanced NSCLC
NSCLC: Moving Second-Line Therapies to Frontline Setting
Helena A. Yu, MD, and Joshua K. Sabari, MD, look to the future of frontline treatment in EGFR exon 20–mutated non–small cell lung cancer.
Clinical Implications of Real-World Amivantamab Data in NSCLC
Lung cancer experts discuss how these real-world data comparing amivantamab with alternative therapies may impact their clinical practice.
Overview of Real-World Comparative Data for Amivantamab in NSCLC
Joshua K. Sabari, MD, and Helena A. Yu, MD, discuss real-world data comparing amivantamab with other therapies in EGFR exon 20–mutated non–small cell lung cancer.
Real-World Analysis of Amivantamab vs Other Therapies in Exon 20–Mutated NSCLC: Methods
A comprehensive overview of the methods utilized in a real-world analysis of amivantamab vs other therapies in patients with EGFR exon 20–mutated NSCLC.
CHRYSALIS: Amivantamab in Patients with Advanced NSCLC
Expert oncologists review the CHRYSALIS trial, which resulted in the approval of amivantamab in the second line for patients with locally advanced or metastatic NSCLC with exon 20 mutations.
Treatment Options for Patients with EGFR Exon 20–Mutated NSCLC
Experts on non–small cell lung cancer discuss treatment options for patients with EGFR exon 20 mutations in the first line and beyond.
Overview of EGFR Exon 20 Mutations
Joshua K. Sabari, MD, and Helena A. Yu, MD, experts on non–small cell lung cancer, give an overview of EGFR exon 20 insertion mutations.
2 Clarke Drive Cranbury, NJ 08512